GENE ONLINE|News &
Opinion
Blog

Merck
AstraZeneca Taps China’s AmoyDx for Companion Diagnostics
2022-04-19
EUA of Monoclonal Antibodies Revoked: Are Oral COVID Drugs the Only Hope?
2022-04-06
Merck Breaks Off Keytruda Combo Trial with AstraZeneca, Begins Another with Imugene
2022-03-16
China’s InxMed Raises $50 Million to Inhibit Cancer-Resisting FAKs
2022-03-07
GeneOnline’s Top 10 M&As of 2021
2022-01-11
FDA Gives Emergency Approval to Merck’s COVID-19 Pill after Giving Similar Nod to Pfizer’s Tablets
2021-12-24
Updated Trial Data Shows Lower Efficacy for Merck’s Oral COVID-19 Pill
2021-11-26
Merck’s Keytruda Bags FDA Approval for Early Kidney Cancer in Adjuvant Setting
2021-11-18
HPV Vaccination Cuts Cervical Cancer Cases by Nearly 90%: Study
2021-11-05
Singapore Becomes Latest Asian Country to Sign Merck Deal for Oral COVID-19 Pill
2021-10-06
Merck Announces Its Oral COVID-19 Drug Cuts Risk of Hospitalization and Death by 50%
2021-10-01
Merck Acquires Acceleron for $11.5 Billion, Gaining Access to a Phase 3 Cardiovascular Asset
2021-09-30
Merck Fortifies Oncology Pipeline with FDA Win for HIF-2α Inhibitor, Welireg
2021-08-17
Merck’s Keytruda Shows Survival Benefit as Adjuvant Therapy in Stage II Melanoma
2021-08-09
Merck’s FDA approval for Pneumonia Vaccine Sets Up Collision Course with Pfizer
2021-07-20
1 2 3 4 5 7
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top